Pfizer Suspends Sales of Bextra
April 7, 2005. Pfizer Inc. on Thursday agreed to suspend sales and marketing of the arthritis drug Bextra at the request of U.S. drug regulators, who said the risks, including Stevens Johnson Syndrome (SJS), outweigh the benefits of the drug. (abcnews.com).
Bextra causes Stevens-Johnson syndrome and toxic epidermal necrolysis -- two forms of the same life-threatening skin disease that cause rash, skin peeling, and sores on the mucous membranes.
< read more >